Ischemia-Reperfusion Injury Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 29 18:10 2022
Ischemia-Reperfusion Injury Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Ischemia-Reperfusion Injury Market
DelveInsight’s “Ischemia-Reperfusion Injury Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Ischemia Reperfusion Injury, historical and forecasted epidemiology as well as the Ischemia Reperfusion Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Ischemia-Reperfusion Injury Market Insights, Epidemiology, and Market Forecast-2032report delivers an in-depth understanding of the Ischemia Reperfusion Injury, historical and forecasted epidemiology as well as the Ischemia Reperfusion Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Ischemia Reperfusion Injury market report provides current treatment practices, emerging drugs, Ischemia Reperfusion Injury market share of the individual therapies, current and forecasted Ischemia-Reperfusion Injury market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Ischemia-Reperfusion Injury treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Ischemia Reperfusion Injury market.

 

Some of the key facts of the Ischemia- Reperfusion Market Report:

  • According to the American Heart Association update in 2012, in the US, someone experiences a stroke every 40s and, on average, a person dies from stroke every 4 minutes
  • The main cause of IRI is organ transplantation, patient recovered from cardiac arrest, and lysing thrombi. Severe reperfusion injury is the most common cause of early death following lung transplantation. The condition occurs in about 15% of all lung transplant recipients and has a mortality rate in excess of 40%.
  • According to Cancer Research UK, in England in 2016 there were 45,960 registrations of newly diagnosed cases of malignant neoplasm of breast and the directly age-standardized rate per 100,000 population was 169.2 for all cases and approximately 55,545 cases in the UK

 

Got queries? Click here to know more about the Ischemic Reperfusion Market Landscape

 

 Ischemic Reperfusion Overview

Ischemia-reperfusion Injury (IRI) is defined as the paradoxical exacerbation of cellular dysfunction and death, following restoration of blood flow to previously ischemic tissues.

Reestablishment of blood flow is essential to salvage ischemic tissues. Ischemia-reperfusion injury occurs when blood supply, perfusion, and concomitant reoxygenation is restored to an organ or area following an initial poor blood supply after a critical time period. It contributes to mortality and morbidity in numerous pathological conditions in emergency medicine, including trauma, ischemic stroke, myocardial infarction, and post-cardiac arrest syndrome

Severe reperfusion injury (primary graft failure, ischemia-reperfusion injury) is the most common cause of early death following lung transplantation. Some of the major causes of IRI is organ transplantation, patient recovered from cardiac arrest, and lysing thrombi. Ischemia Reperfusion Injury shows gender-based differences: It is lower in females as compared to males, similar to their primary causes such as stroke and other thrombus.Ischemia-reperfusion injury has been treated using several therapeutic gases, including hydrogen (H2), hydrogen sulfide (H2S), NO, and carbon monoxide (CO).  The first line of treatment is always thrombolytic therapy or an invasive revascularization procedure. Revascularization is done in order to prevent initial extensive cellular damage.

 

 Ischemic Reperfusion Market Epidemiological Insights:

 

  • As per Ikhlas & Atherton (2021), the prevalence of reperfusion injury is directly proportional to the duration for which ischemia remains. It has been shown through studies that those receiving thrombolytic therapy within 1 hour had a 51% infarct size reduction compared to the 31% reduction seen in those receiving treatment after 1 to 2 hours.
  • The incidence of ischemic injury is high: myocardial infarction, stroke, and other thrombotic events affect more than 1.3 million individuals each year in the US alone.
  • According to Cross et al. (2002), female hearts exhibit less ischemia and reperfusion injury than males under conditions that promote Ca2+ loading such as stimulation of β-adrenoceptors or increased external Ca2+ concentration

 

 Ischemic Reperfusion Market  Epidemiological Segmentation 

  •   Ischemic Reperfusion Total lncident Cases 
  •  Ischemic Reperfusion Organ-specific Incident Cases 
  •  Ischemic Reperfusion Gender-specific Incident Cases 
  •  Ischemic Reperfusion Age Specific Incident Cases

 

Ischemic Reperfusion Market Outlook 

The Ischemia Reperfusion Injury market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Ischemia Reperfusion Injury market trends by analyzing the impact of current Ischemia Reperfusion Injury therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Ischemia Reperfusion Injury market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Ischemia Reperfusion Injury market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Ischemia Reperfusion Injury market in 7MM is expected to witness a major change in the study period 2019-2032.

 

 Ischemic Reperfusion Key Companies  

 

  •  X4 Pharmaceuticals
  • Plerixafor
  •  and many others

 

Ischemic Reperfusion  Therapies 

  •  Mavorixafor
  •  NIAID
  • and many others

 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  • Executive Summary of  Ischemic Reperfusion
  •  Disease Background and Overview
  • Epidemiology and patient population
  •  The United States 
  •  EU 5
  •   Ischemic Reperfusion Emerging Therapies
  •   Ischemic Reperfusion Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •   Ischemic Reperfusion Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer

Click here to read more about  Ischemic Reperfusion Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/